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ABSTRACT
Objectives: Our objective was to evaluate in our clinic the perinatal outcomes of patients diagnosed with ICP based on 
pre-treatment maternal serum bile acid levels, attempt to identify the risk group and review the literature in light of this 
information.
Material and methods: In total, 370 patients diagnosed with ICP were included in the study, divided into two groups based 
on the fasting total serum bile acid level before UDCA (Group 1: 10 ≥ 40 μmol/L, and Group 2: ≥ 40 μmol/L). The groups 
were examined for clinical characteristics and pregnancy outcomes.
Results: It was found that preterm delivery and neonatal intensive care need increased at a serum bile acid cut-off value of 
34 μmol/L. Regardless of serum bile acid, significantly higher rates of meconium-stained amniotic fluid and foetal distress 
were observed in patients whose diagnoses were made before 34 weeks of gestation.
Conclusions: Foetal complications over 40 μmol/L of serum bile acid were significantly increased. However, slightly lower 
levels cut-off values (34 μmol/L) were obtained in terms of preterm birth and neonatal intensive care need. The incidence 
of meconium-stained amniotic fluid and foetal distress was higher in patients whose diagnosis were made before 34 weeks 
of gestation.
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INTRODUCTION
Intrahepatic cholestasis of pregnancy (ICP) is a pregnancy-
specific liver disease. ICP, which is frequently seen in the second 
or third trimester, is also the most common liver disease in 
pregnancy. Maternal pruritus and elevated serum bile acid 
and/or transaminase levels are characteristic findings. ICP 
prevalence varies between regions and races. The incidence 
of the disease is reported to be 0.1% to 15.6% worldwide [1]. 
The maternal effects of ICP have a benign course, although 
ICP can lead to important consequences in the foetus and 
can cause many foetal complications, including intrauterine 
foetal loss [2]. Human and animal studies have shown that 
the transplacental transfer of bile acids is impaired in ICP 
patients [3, 4].
To avoid foetal complications caused by ICP, delivery 
either after foetal lung maturation or 37 weeks is a frequently 
used approach [4, 5]. It is thought that markedly elevated 
bile acids and advanced gestation are more important in 
the development of foetal complications [2]. As a result, 
there are data showing that the same approach should not 
be used in every ICP patient; in particular, a more expedient 
approach should be taken for patients with serum bile acids 
below 40 μmol/L, although this issue is still unclear.
Objectives
The objective of this study was to examine the fasting 
serum bile acid levels of ICP patients between specific 
ranges and to evaluate foetal complications in patients 
diagnosed with ICP, examining perinatal outcomes in these 
patient groups. Since ICP patients with maternal total serum 
bile acids < 40 μmol/L are considered to be at low risk in the 
literature, we evaluated patients in two groups according 
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to serum bile acid level 40 μmol/L. We also reviewed foetal 
outcomes in ICP patients before or after 34 weeks gestation.
MATERIAL AND METHODS
There were 21,000 pregnant women who gave birth 
at Samsun Training and Research Hospital between 2012–
2018 and who were followed-up. Overall, 436 of these 
patients was diagnosed with ICP. The incidence of cholestasis 
of pregnancy in our hospital was found to be 2%. Of these 
patients with ICP, 370 were included in the study. Patients free 
from any liver disease or skin pathology who had persistent 
pruritus without primary skin lesions, elevated fasting total 
serum bile acid (≥ 10 μmol/L) and/or liver enzymes were 
diagnosed with ICP. Sixty-six patients diagnosed with ICP 
were not included in the study. Patients who had multiple 
pregnancies and patients with congenital or chromosomal 
anomalies were not included in the study. Likewise, patients 
who were diagnosed with chronic liver disease and viral 
infection (hepatitis A, B, C infections) were excluded from 
the study. Ursodeoxycholic acid (UDCA) was started (250 mg 
three times a day) in patients diagnosed with ICP. Based 
on the patient’s symptoms, UDCA dosage was increased 
after 1–2 weeks (maximum 2000 mg/day) if needed. The 
gestational week of the patients was calculated according 
to the reliable last menstrual period and/or ultrasonographic 
measurements in the early gestational period. Patients were 
followed up with biophysical profile 1–2 times per week 
based on their respective gestational week.
Blood was collected for the determination of fasting total 
serum bile acid in patients who presented to the hospital 
with pruritus without primary skin lesions. Maternal fasting 
total serum bile acids were sent to the Düzen Laboratory in 
Ankara as a reference centre. The patients did not receive 
UDCA before the biliary acid results came back and ICP 
diagnosis was made. Other laboratory tests were performed 
in the biochemistry department of our hospital. If gestational 
week was appropriate for follow-up, maternal fasting serum 
bile acids were reworked one week after UDCA was started 
and weekly serum biochemical tests were performed.
Patients who were diagnosed with ICP and who were 
included in the study were divided into two groups (Group 1: 
10–40 μmol/L, and Group 2: ≥ 40 μmol/L) based on the 
fasting total serum bile acid level before UDCA was initiated. 
Maternal demographics, medical comorbidities, and serum 
biochemical parameters were obtained from the hospital 
database. Delivery induction was achieved with intravenous 
oxytocin infusion following cervical ripening with 10 mg 
prostaglandin E2.
Perinatal outcomes of ICP patients included in the study 
were evaluated by the groups divided based on the serum 
bile acid levels. The gestational week at diagnosis, week of 
delivery, route of delivery, birth weight, intrauterine growth 
retardation (IUGR), foetal distress, stillbirth, the need for 
intensive care (NICU) and intubation of the baby, meconium-
stained amniotic fluid, and five minute Apgar score were 
recorded. The Apgar score includes newborn breathing, 
heartbeat, muscle tone, laryngeal reflex and skin colour; 
Apgar scores ≤ 7 were considered to be low. Delivery before 
37 weeks of gestation was considered preterm birth. If foetal 
weight was less than 10% per centile based on the gestational 
week, IUGR was accepted. Patients with severe cholestasis of 
pregnancy were delivered between 34–37 weeks considering 
maternal complications and foetal condition, and a delivery 
was planned immediately for patients whose diagnosis was 
made at or after 38 weeks of gestation. In patients with mild 
cholestasis, delivery was planned at 37–38 weeks.
Statistical analysis
The descriptive statistics for continuous variables 
were expressed in mean ± standard deviation or 
median (minimum-maximum), while nominal variables 
were expressed as the number and percentage (%). The 
significance of the difference between the mean values of 
the groups was evaluated using the Student’s t-test, while 
the significance of the difference in the median values was 
evaluated using the Mann-Whitney U test. Categorical 
data were compared by Chi-square distribution. Univariate 
Binary Logistic Regression analysis was used to analyse 
the  effect of  the cholestasis of pregnancy on perinatal 
outcomes. A p value of < 0.05 was considered statistically 
significant. Statistical analysis was performed using SPSS for 
Windows version 22 software (SPSS Inc., Chicago, IL, USA).
RESULTS
In total, 21,000 deliveries took place in our 
hospital between 2013 and 2018. Of these patients, 
436 experienced cholestasis of pregnancy, and 58 were 
multiple pregnancies. The study included 370 patients with 
cholestasis of pregnancy who were singleton pregnancies.
The demographics and laboratory characteristics of 
the patients are presented in Table 1. The mean age of the 
patients was 27.7 ± 5.3 (range 18–42) with 56% nulliparous 
and 44% multiparous. Mean gestational week at diagnosis 
was 33.1 ± 2.8 (range 27–39). The mean gestational week at 
delivery was 36.5 ± 1.2 (range 32–39). A total of 83 patients 
(22.4%) gave birth before 37 weeks and 20 of these patients 
(5.4%) gave birth before 34 weeks. 
The indication for the induction of labour was cholestasis 
of pregnancy in most patients. There was no intrauterine 
foetal demise in any of the patients. The incidence of 
preeclampsia and gestational diabetes mellitus was 4.9% 
and 6.9%, respectively.
Patients were divided into two groups based on the 
fasting serum bile acid level at diagnosis. In the first group, 
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serum bile acid levels were < 40 μmol/L (mild cholestasis, 
246 patients), while they were ≥ 40 μmol/L (severe cholestasis, 
124 patients) in the second group. The demographics and 
clinical data of both groups are presented in Table 2.
The gestational week at presentation was 35 weeks 
(range 29–39) in the mild cholestasis group and 32 weeks 
(range 27–36) in the severe cholestasis group (p < 0.001).
The gestational week at diagnosis was statistically 
significantly earlier in patients with serum bile 
acid ≥ 40 μmol/L. ALT, AST, ALP and total bilirubin levels were 
significantly higher in the severe cholestasis group versus 
mild cholestasis group (p < 0.001). Similarly, the decrease in 
serum bile acid, ALT, AST, ALP and total bilirubin levels was 
faster in the mild cholestasis group versus severe cholestasis 
group one week after the treatment (p < 0.001). 
When compared, there was also a significant difference 
in the incidence of cholestasis in the previous pregnancy 
between the two groups. The prevalence of cholestasis in 
a previous pregnancy in the mild cholestasis group was 
12.2% (30 patients), while it was 39.5% (49 patients) in the 
severe cholestasis group (p < 0.001) (Tab. 2).
Table 3 compares the delivery data and perinatal 
outcomes of the patients based on the groups. Women 
with severe cholestasis of pregnancy were delivered earlier 
in their gestation. Similarly, when the birth weight was 
compared between the two groups, the birth weight of 
babies in the severe cholestasis group was significantly 
lower than that of the mild cholestasis group (p < 0.001). 
There was no significant difference between the two groups 
in terms of route of delivery. 
When the perinatal outcomes were compared between 
the two groups, meconium-stained amniotic fluid was 
observed in 7.7% of patients in the mild cholestasis group and 
25% of patients in the severe cholestasis group (p < 0.001). 
Similarly, the rate of foetal distress was significantly higher in 
the severe cholestasis group (p < 0.004). Five-minute Apgar 
score, neonatal intensive care need and intubation rate were 
significantly higher in the severe cholestasis group (p < 0.001, 
p < 0.001 and p < 0.008, respectively). When the preterm 
delivery rates were compared between the two groups, the 
number of deliveries before 37 weeks was 32 (13%) in the mild 
cholestasis group and 51 (51.1%) in the severe cholestasis 
group (p < 0.001). Similarly, when deliveries before 34 weeks 
were compared, preterm birth rates were significantly higher 
in the severe cholestasis group (p < 0.001) (Tab. 3).
According to the ROC curve analysis demonstrating 
the significance of the pre-treatment bile acid levels in the 
determination of preterm births and NICU need between 
the groups, the serum bile acid cut-off value was found to 
Table 1. Clinical characteristics of study population
n 370
Age [years] (mean ± SD) 27.7 ± 5.3
Gravidity [range] 1–7
Gestational age at diagnosis [weeks] 
(mean ± SD) 33.1 ± 2.8
Gestational Diabetes [%] 6.9
Preeclampsia [%] 4.9
Intrauterine growth retardation [%] 5.1
Gestational age at delivery [weeks] 
(mean ± SD) 36.5 ± 1.2
Delivery < 37 weeks of gestation [n] 83
Delivery < 34 weeks of gestations [n] 20
Delivery methods (%9
Vaginal 42%
Caesarean section 58%
Total bile acid at diagnosis / after 
treatment [µmol/L] (mean ± SD) 46.0 ± 41.67 / 20 ± 6.8
ALT at diagnosis / after treatment 
[U/L] (mean ± SD) 85.1 ± 69.6 / 33.3 ± 28.9
AST at diagnosis /after treatment 
[U/L] (mean ± SD) 79.9 ± 55.7 / 32.2 ± 27.1
Total bilirubin at diagnosis / after 
treatment [µmol/L] (mean ± SD) 1.5 ± 4.8 / 1.3 ± 0.7
ALP at diagnosis / after treatment 
[µmol/L] (mean ± SD) 246.8 ± 131.7 / 203.0 ± 103.1
Table 2. Demographic and laboratory findings of severe and mild 
cholestasis
Mild Cholestasis (n = 246)
Severe 
Cholestasis 
(n = 124)
p value
Age [years] 27.7 ± 5.2 27.6 ± 5.4 0.937
Gravidity 1 (1–6) 1 (1–7) 0.446
Parity 0 (0–9) 0 (0–5) 0.456
BMI (kg/m²) 32.2 ± 5.2 33.0 ± 6.1 0.375
Total bile acids at diagnosis 
[μmol/L] 25.1 ± 8.0 87.7 ± 19.5 0.001*
Gestational age at diagnosis 
[weeks] 35 (29–39) 32 (27–36) 0.001*
AST at diagnosis [U/L] 62.1 ± 34.1 115.1 ± 71.5 0.001*
ALT at diagnosis [U/L] 62.3 ± 35.9 130.1 ± 94.3 0.001*
Total bilirubin at diagnosis 
[μmol/L] 1.1 ± 0.4 1.8 ± 0.9 0.001*
ALP after treatment [U/L] 208.3 ± 72.8 323.3 ± 180.7 0.001*
AST after treatment [U/L] 22.6 ± 15.0 51.5 ± 34.6 0.001*
ALT after treatment  [U/L] 24.0 ± 16.5 45.1 ± 38.0 0.001*
Total bilirubin after 
treatment [μmol/L] 1.0 ± 0.4 1.7 ± 0.9 0.001*
ALP after treatment [U/L] 173.3 ± 54.5 262.1 ± 143.7 0.001*
Total bile acids after 
treatment [μmol/L] 18.9 ± 4.8 24.0 ± 8.8 0.001*
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be 34.40 µmol/L and 34.71 µmol/L, respectively (for preterm 
birth Area Under Curve = 0.703, p = 0.001 (95% CI: 0.644–
0.763) (Fig. 1); for NICU need Area Under Curve = 0.677, 
p = 0.001 (95% CI: 0.584–0.771) (Fig. 2).
When the foetal results were compared based on the 
gestational week at diagnosis without the evaluation of 
serum bile acid, significantly higher rates of meconium-
stained amniotic fluid and foetal distress were observed 
in patients whose diagnosis were made before 34 weeks 
gestation (p < 0.001) (Tab. 4).
DISCUSSION
Our study found 3 important points: 1) In patients with 
serum bile acid ≥ 40 μmol/L, perinatal complications were 
significantly increased compared to patients with mild 
cholestasis; 2) Foetal complications (preterm birth and 
neonatal intensive care need) are significantly increased 
at a serum bile acid cut-off value of 34 μmol/L, although 
serum bile acid ≥ 40 μmol/L is a value that is also used in 
the definition of severe cholestasis in the literature; and 3) 
Higher rates of meconium-stained amniotic fluid and foetal 
Table 3. Perinatal outcomes of severe and mild cholestasis
Mild cholestasis (Total bile 
acids < 40 μmol/L)
(n = 246)
Severe cholestasis (Total 
bile acids > 40 μmol/L)
(n = 124)
Odds Ratio (%95 confidence) p values
Gestational age at delivery [weeks] 37 (33-39) 36 (32-38) 0.001*
Preterm delivery < 37w [n, %] 32 (13%) 51 (51.1%) 4.67 (2.79–7.82) 0.001*
Preterm delivery < 34w [n, %] 6 (2.4%) 14 (11.3%) 5.09 (1.90–13.60) 0.001*
Birth weight [g] 2990 (1850–4250) 2490 (1670–3550) 0.001*
Mode of delivery
[n, %]
Vaginal
Casarean section
148 (60.2 %)
98 (39.8 %)
65 (52.4 %)
59 (47.6 %) 1.37 (0.88–2.11)
0.497
0.155
Meconium staining [n, %] 19 (7.7%) 31 (25.0%) 3.98 (2.14–7.40) 0.001*
Fetal distress [n, %] 34 (13.8%) 32 ( 25.8%) 2.16 (1.26–3.72) 0.004*
5 min Apgar score (mean ± SD) 9 (5–10) 8 (5–10) 0.001*
Perinatal mortality [n] 0 0 N.A
Neonatal unit admission [n, %] 38 (15.4%) 41 (33.0%) 4.19 (2.17–8.10) 0.001*
Entubation [n, %] 22 (8.9%) 13 (18.5%) 2.31 (1.23–4.35) 0.008*
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Fıgure 1. ROC curve for the prognostic value of total bile acids at 
diagnosis and preterm birth
Figure 2. ROC curve for the prognostic value of total bile acids at 
diagnosis and neonatal unit admission
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distress were observed in patients whose ICP diagnosis were 
made before 34 weeks of gestation compared to the patients 
whose ICP diagnosis were made after 34 weeks gestation.
Our study has certain strengths. Participants from our 
single hospital had the same criteria for diagnosis and 
similar antenatal monitoring of ICP. Bloods from patients 
obtained to determine the serum bile acid levels were 
studied in a private reference laboratory at a single centre 
(Ankara Düzen Laboratory). The study also has several 
limitations. First, we used a retrospective design, due to 
the rarity of the disease. Second, although large for studies 
of intrahepatic cholestasis of pregnancy, our sample size 
limited our ability to make definitive conclusions about rare 
foetal complications. Lastly, our study may have errors in that 
the active management of cholestasis could have resulted in 
a decreased frequency of adverse foetal outcomes.
The rate of cholestasis of pregnancy in our study was 
2% and the rate of severe ICP was found to be 33% in all ICP 
patients. In previous studies, the incidence of cholestasis 
of pregnancy was 0.7–1.5% in the UK and severe ICP was 
observed in 15% of all ICP patients [6–8]. This ratio was found 
to be higher in our region.
According to the literature, it seems that ICP patients 
have an increased risk of preeclampsia and gestational 
diabetes [6, 7, 9]. Our study also found that the rate of 
gestational diabetes in ICP patients was higher than in 
women with normal pregnancies, but there was no difference 
in preeclampsia.
In our findings, foetal distress and meconium-stained 
amniotic fluid in ICP patients diagnosed before 34 weeks 
of gestation were significantly higher than in ICP patients 
diagnosed after 34 weeks of gestation. We demonstrated 
that in ICP patients diagnosed before 34 weeks of gestation, 
the frequency of perinatal complications, especially foetal 
distress and meconium-stained amniotic fluid, are increased. 
Estiu et al. also reported an association between meconium-
stained amniotic fluid and lower gestational age both at 
diagnosis and at birth in 382 ICP patients [7]. Similarly, it 
was stated by Madazlı et al. that foetal complications such 
as preterm delivery, RDS and IUGR were significantly higher 
in patients who were diagnosed before 30 weeks than after 
34 weeks of gestation [10]. 
Although ICP is a relatively benign disease for the mother, 
there are many risks for the babies, including preterm 
delivery, foetal distress, meconium-stained amniotic fluid, 
and foetal demise. Glandz et al. concluded that the risk of 
foetal complications does not occur until serum bile acid 
levels exceed 40 μmol/L [5]. Since then, other studies have 
also reported increased foetal complications with serum bile 
acid levels over 40 μmol/L [11–13]. Cui et al. reported that 
total bile acid levels ≥ 40 μmol/L are considered to represent 
severe disease [12]. Although several studies have reported 
a positive correlation between elevated serum total bile 
acids and an increased risk of perinatal complications, 
there are also controversial results [14, 15]. A study by 
Oztas et al. stated that there is no relationship between 
serum total bile acid levels and preterm delivery [14]. 
Madazlı et al. also stated that there was no significant 
difference between the incidence of RDS, foetal distress 
and preterm delivery according to serum bile acid levels [10]. 
In our study, meconium-stained amniotic fluid and foetal 
distress rates were significantly increased with serum bile 
acid levels over 40 μmol/L. Similarly, neonatal intensive care 
need and neonatal intubation rates were also significantly 
increased with serum bile acid levels over 40 μmol/L. This 
study is especially important, as it showed that perinatal 
complications increase at a lower level of serum bile acid 
with a cut-off level of 34 μmol/L. A cut-off level of 34 μmol/L 
is first reported in the current study. 
One of the major complications of cholestasis of 
pregnancy is prematurity [2, 16, 17]. In the literature, the 
incidence of prematurity in ICP patients is 19–60% [6]. 
Preterm delivery, which causes prematurity in patients 
with cholestasis of pregnancy, can be spontaneous and 
iatrogenic. In vitro studies have shown that serum bile 
acids, in particular colic acid, increase the expression of 
oxytocin receptor, and myometrial responses to oxytocin. 
Spontaneous preterm labour may be explained by a dose-
dependent bile acid effect on myometrial contractility [17, 18]. 
In our study, about half (51%) of the patients with serum bile 
acid levels above 40 μmol/L at diagnosis delivered before 
37 weeks. Of these patients, 49% delivered spontaneously 
and 51% were iatrogenic premature birth. 
In our study, distinct from other studies, the serum bile 
acid level of 34 μmol/L was determined as the cut-off value 
for preterm birth. In the literature, a maternal serum bile acid 
level of ≥ 40 μmol/L was demonstrated as the threshold 
for foetal complications in most publications. In our study, 
we also observed an increase in all foetal complications 
Table 4. Comparison of pregnancy outcomes of intrahepatic 
cholestasis of pregnancy ≥ 34 weeks and < 34 weeks
≥ 34 weeks 
(n = 20)
< 34 weeks 
(n = 350) p values
Total bile acids at 
diagnosis (µmol/L) 66.73 ± 11.13 44.97 ± 22.35 0.023
Total bile acids after 
treatment (µmol/L) 17.79±14.89 10.15 ± 7.41 0.001
Meconium staining 
[n, %] 8 (40.0%) 42 (% 12.0) 0.001
Fetal distress [n, %] 9 (45.0%) 57 (% 16.3) 0.001
Mode of delivery [n, %]
Vaginal
Cesarean section
7 (35%)
13 (65%)
206 (58.9%)
144 (41.1%)
0.011
0.036
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over 40 μmol/L (preterm delivery, meconium-stained am-
niotic fluid, foetal distress, neonatal intensive care need 
and newborn intubation rates). We also found the serum 
bile acid level of 34 μmol/L to be the cut-off value for the 
determination of risk of preterm birth and neonatal inten-
sive care need.
The incidence of stillbirth is 1.5% in ICP in the literature [11]. 
The mechanism causing stillbirth in ICP is poorly 
understood. At autopsy, the babies have no signs of chronic 
uteroplacental insufficiency, but do have evidence of acute 
anoxia [11, 18]. It seems that intrauterine foetal demise 
risk increases after 37 weeks of gestation, also related to 
the higher serum level of bile acids in ICP. Examination of 
the placental changes in ICP patients support the theory 
of an acute event that can cause foetal demise [4]. The 
possible mechanisms for acute foetal demise may be cardiac 
arrhythmia or sudden vasospasm of placental chorionic 
surface vessels due to bile salts. Further evidence for this 
hypothesis comes from the studies that cultured neonatal 
cardiomyocytes show decreased contractility and develop 
arrhythmogenic activity when exposed to bile acids [19, 20]. 
There were no intrauterine deaths in our study. The reason 
for this might be that the timing of delivery in ICP patients 
was planned to be 37–38 weeks at the latest, immediate 
delivery with labour induction or caesarean section was 
planned in patients diagnosed with ICP after 38 weeks and 
later, while patients with severe cholestasis patients with 
higher bile acid levels were delivered at 34–37 weeks.
CONCLUSIONS
In conclusion, we found that foetal adverse effects are 
more frequent when the cholestasis was recognised before 
34 weeks of pregnancy or when the serum bile acids are 
higher than 34 μmol/L. Cholestasis of pregnancy is still not 
a clearly manageable disease and the timing of delivery and 
prediction of foetal complications are still unclear in the 
prevention of foetal complications. Both a gestational age 
of 34 weeks and serum bile acid levels of 34 µmol/L at the 
time of ICP diagnosis seem to be important independent 
factors to predict foetal complications in ICP patients.
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